Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2003-03-20
2010-10-05
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S250100, C424S249100, C514S023000, C536S123100
Reexamination Certificate
active
07807181
ABSTRACT:
Provided herein are mutant strains ofNeisseria meningitidiswhich produce Kdo-free lipid A as well as the Kdo-free lipid A molecules and immunogenic compositions containing such Kdo-free lipid A molecules from aNeisseriastrain containing a genetically stable mutation which inactivates a gene selected from the group consisting of genes encoding arabinose-5-phosphate isomerase, CMP-Kdo synthetase and CMP-Kdo transferase.N. meningitidisNMB206 is a specifically exemplified strain which harbors a stable insertion mutation in the gene (kpsF) encoding A5P isomerase; strain NMB-249 is a specifically exemplified strain with a stable insertion mutation in the gene (kdtA) encoding CMP-Kdo synthetase, and strain NMB259 is specifically exemplified strain with a stable insertion mutation in the gene (kdsB) encoding CMP-Kdo transferase. Also provided by the present invention are methods for the production of Lipid A flee of 3-keto-3-deoxyoctanoic acid using these genetically stableN. meningitidismutants. Also describes is pYT250, a plasmid functional in neisseriae and in enterics such asEscherichia coli.
REFERENCES:
patent: 5705161 (1998-01-01), Van Der Ley et al.
patent: 5952313 (1999-09-01), Carlson
patent: WO 00/22430 (2000-04-01), None
patent: WO 00/66791 (2000-11-01), None
Limjuco et al. J. Gen. Microbiol. 104: 187-191, 1978.
Lee et al. Infect. Immun. 63: 2508-2515, 1995.
Lodowska et al. Post py higieny i medycyny doswiadczalnej (Online), 61: 106-121, 2007, abstract.
Bateman, A. (1999) “The SIS domain: a phosphosugar-binding domain,”Trends Biochem. Sci. 24:94-95.
Belunis et al. (May 1992) “Biosynthesis of endotoxins. Purification and catalytic properties of 3- deoxy-D-manno-octulosonic acid transferase fromEscherichia coli,” J. Biol. Chem. 267(14): 9988-9997.
Bigham et al. (Jun. 1984) “Inhibition of arabinose 5-phosphate isomerase. An approach to the inhibition of bacterial lipopolysaccharide biosynthesis,”J. Med. Chem. 27:717-726.
Brabetz et al. (Aug. 2000) “3-Deoxy-D-manno-oct-2-ulosonic acid (kdo) transferase ofLegionella pneumophilatransfers two kdo residues to a structurally different lipid A precursor ofEscherichia coli,” J. Bacteriol. 182: 4654-4657.
Brandtzaeg et al.(Sep. 1992) “Compartmentalization of lipopolysaccharide production correlates with clinical presentation in meningococcal disease,”J. Infect. Dis. 166:650-652.
Brozek et al. (Sep. 1990) “Biosynthesis of lipid A inEscherichia coli. Acyl carrier protein-dependent incorporation of laurate and myristate,”J. Biol. Chem. 265:15410-15417.
Christodoulides, et al. (Jan. 2000) “Interaction of Primary Human Endometrial Cells withNeisseria gonorrhoeaeExpressing Green Flourescent Protein,”Mol. Microbiol. 35(1):32-43.
Cieslewicz et al. (Dec. 1993) “Cloning, Sequencing, Expression, and Complementation Analysis of theEscherichia coliK1 Region 1 Gene, KpsE, and Identification of an Upstream Open Reading Frame Encoding a Protein with Homology to GutQ,”J. Bacteriol. 175(24):8018-8023.
Cieslewicz et al. (Jun. 1996) “Thermoregulation ofkpsF, the first region 1 gene in thekpslocus for polysialic acid biosynthesis inEscherichia coliK1,”J. Bacteriol. 178:3212-20.
Cieslewicz et al. (Oct. 1997) “Reduced polysialic acid capsule expression inEscherichia coliK1 mutants with chromosomal defects inkps, ” Mol. Microbiol. 26:237-249.
Finke et al. (Jul. 1991) “Biosynthesis of theEscherichia coliK5 polysaccharide, a representative of group II capsular polysaccharides: polymerization in vitro and characterization of the product,”J. Bacteriol. 173:4088-4094.
Frecer et al. (Feb. 2000) Interpretation of biological activity data of bacterial endotoxins by simple molecular models of mechanism of action,Eur. J. Biochem. 267:837-852.
Frecer et al. (Jun. 2000) “Molecular dynamics study on lipid A fromEscherichia coli: insights into its mechanism of biological action,”Biochim. Biophys. Acta1466:87-104.
Galanos et al. (Apr. 1984) “Endotoxic properties of chemically synthesized lipid A part structures. Comparison of synthetic lipid A precursor and synthetic analogues with biosynthetic lipid a precursor and free lipid A,”Eur. J. Biochem. 140:221-227.
Gangloff et al. (Mar. 1999) “Lipopolysaccharide structure influences the macrophage response via CD14-independent and CD14-dependent pathways,”Clinical Infectious Diseases28:491-496.
Goldman et al. (Apr. 1988) “Lipid A precursor fromPseudomonas aeruginosais completely acylated prior to addition of 3-deoxy-D-manno-octulosonate,”J. Biol. Chem. 263:5217-5223.
Gotschlich et al. (Sep. 1981) “Lipid on capsular polysaccharides of gram-negative bacteria,”J. Biol. Chem. 256: 8915-21.
Hawkins et al. (Feb. 2002) “A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity,”J Pharmacol. Exp. Ther. 300:655-661.
Hirschfeld et al. (Mar. 2001) “Signaling by Toll-Like Receptor 2 and 4 Agonists Results in Differential Gene Expression in Murine Macrophages”Infect. Immun. 69:1477-1482.
Hitchcock et al. (Apr. 1983) “Morphological heterogeneity amongSalmonellalipopolysaccharide chemotypes in silver-stained polyacrylamide gels,”J. Bacteriol. 154:269-277.
Kahler et al. (Mar. 1996) “Inner core biosynthesis of lipooligosaccharide (LOS) inNeisseria meningitidisserogroup B: identification and role in LOS assembly of the alpha1,2 N-acetylglucosamine transferase (RfaK),”J. Bacteriol. 178:1265-1273.
Kahler et al. (Dec. 1998) “The (α2—> 8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup BNeisseria meningitidisto resist the bactericidal activity of normal human serum,”Infect. Immun. 66:5939-5947.
Kahler et al. (Jan. 1998) “Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin),”Crit. Rev. Microbiol. 24: 281-334.
Kathariou et al. (May 1990) “Transposition of Tn916 to Different Sites in the Chromosome ofNeisseria meningitidis: A Genetic Tool for Meningococcal Mutagenesis,” Mol. Microbiol. 4:729-735.
Levin et al. (Aug. 1996) “Cloning, Complementation, and Characterization of anrƒaE Homolog fromNeisseria gonorrhoeae,” J. Bacteriol. 178(15):4571-4575.
Loppnow et al. (May 1989) “IL-1 induction-capacity of defined lipopolysaccharide partial structures, ”J. Immunol. 142:3229-3238.
Luderitz et al. (Jul. 1984) “Lipopolysaccharides: structural principles and biologic activities,”Rev. Infect. Dis. 6:428-431.
MacKinnon et al. (Nov. 1993) “Demonstration of lipooligosaccharide immunotype and capsule as virulence factors forNeisseria meningitidisusing an infant mouse intranasal infection model,”Microb. Path. 15:359-366.
Matsuyama et al. (Oct. 2001) “Non-standard biological activities of lipopolysaccharide fromHelicobacter pylori,” J. Med. Microbiol, 50:865-869.
Menard et al. (Sep. 1993) “Nonpolar mutagenesis of theipagenes definesIpaB, IpaC, andIpaDas effectors ofShigella flexnerientry into epithelial cells,”J. Bacteriol. 175:5899-5906.
Mohan et al. (Nov. 1994) “Endotoxin biosynthesis inPseudomonas aeruginosa: enzymatic incorporation of laurate before 3-deoxy-D-manno-octulosonate,”J. Bacteriol. 176:6944-6951.
Moran et al. (Dec. 1996) “Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease,”FEMS Immunol. Med. Microbiol. 16:105-115.
Nurminen et al. (May 1985) “Chemical characterization of Chlamydia trachomatis lipopolysaccharide,”Infect. Immun. 48:573-575.
Odegaard et al. (Aug. 1997) “Shortened hydroxyacyl chains on lipid A ofEscherichia colicells expressing a foreign UDP-N-acetylglucosamine O-acyltransferase,”J. Biol. Chem. 272:19688-19696.
Ogawa
Stephens David S.
Tzeng Yih-Ling
Zimmer Shanta
Zughaier Susu
Devi S.
Emory University
Greenlee Sullivan P.C.
LandOfFree
Neisseria mutants, lipooligosaccharides and immunogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neisseria mutants, lipooligosaccharides and immunogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neisseria mutants, lipooligosaccharides and immunogenic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4194217